Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors

Details Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors

2004-05-11

2008-05-06

Chang, Celia (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S112000

Reexamination Certificate

active

07368457

ABSTRACT:
In an embodiment, this invention discloses novel gamma secretase inhibitors of Formulae I:wherein the various moieties are described herein. Also disclosed is a method of treating Alzheimer's disease using a compound of Formula I or a composition comprising the compound of Formula I.

REFERENCES:
patent: 4-247081 (1992-09-01), None
patent: WO 00/50391 (2000-08-01), None
Wang et al. “High performance . . . ” CA 116:91540 (1992).
Goto et al. “Preparation of fivemenbered . . . ” CA 118:213064 (1993).
LeBlanc et al. “Production of . . . ” CA 121:298388 (1994).
Hooper et al. “Membrane protein secretases” CA 126:196601 (1997).
Xia et al. “Relationship between . . . ” CA 139:357800 (2003).
Beal et al. “Degenerative disease of the nervous system” in Harris's principle of internal medicine, 12thed. (1991) p. 2060-2062.
Takeda et al. “Preparation of five membered . . . ” CA 118:213064 (1993).
Bancher et al. “Low prevalence of apolipoprotein . . . ” CA 128:46764 (1997).
Chui et al. “Transgenic mice . . . ” CA 131:86371 (1999).
Nielsen et al. “Novel potent ligands . . . ” J. Med. chem. v.43, p. 2217-2226 (2000).
Obici et al. “A novel ABPP mutation . . . ” Ann. Neurology, v.58,639-644 (2005).
Pear et al. “T-cell acute lymphoblastic . . . ” Curr. Opin. Hematology v.11, p. 426-433 (2004).
Fortini M. “gamma secretase mediated . . . ” Nature Rev. mol. cell. biol. v.3, p. 673-684 (2002).
PCT International Search Report dated May 11, 2004 for corresponding PCT Application No. PCT/US2004/014671.
Takefumi Momose; Shohgo Atarashi, Reaction of N-Benzenesulfonyl-9-Azabicyclo-[3.3.1]Nona-2,6-Diene with Diborane: Failure of Cyclic Hydroboration in the Intramolecularly Faced Diene System,Heterocyclesvol. 6, No. 4 (1977) 469-474 ISSN 0385-5414.
Butcher, J., Alzheimer's amyloid hypothesis gains support, Science and Medicine, The Lancet, vol. 356, Dec. 23/30, 2000, p. 2161.
Hardy, J., et al., The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics, Science's Compass Review, vol. 297, Jul. 19, 2002, pp. 353-356.
Hock, C., et al., Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease, Neuron, vol. 38, May 22, 2003, pp. 547-554.

Affiliated with

Also associated with

Rating

Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3981617